Gastroesophageal Adenocarcinoma Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., Merck, Taiho Pharma, Sichuan Kelun-Biotech, ALX Oncology, Canadian Cancer Tri

DelveInsight's "Gastroesophageal Adenocarcinoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Gastroesophageal Adenocarcinoma, historical and forecasted epidemiology as well as the Gastroesophageal Adenocarcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastroesophageal Adenocarcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroesophageal Adenocarcinoma Market Forecast
https://www.delveinsight.com/sample-request/gastroesophageal-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Gastroesophageal Adenocarcinoma Market Report:
• The Gastroesophageal Adenocarcinoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In March 2025, Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab deruxtecan) demonstrated a clinically significant improvement in overall survival (OS), the primary endpoint, in the Phase III DESTINY-Gastric04 trial involving patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma. This global, randomized, open-label study included 494 participants from Europe, South America, and Asia. The trial evaluated the safety and effectiveness of the antibody-drug conjugate (ADC) compared to ramucirumab plus paclitaxel in patients with second-line HER2-positive unresectable and/or metastatic GEJ adenocarcinoma.
• In January 2025, Merck (NYSE: MRK), known as MSD outside the US and Canada, together with Eisai, announced the results of the Phase 3 LEAP-015 trial. The study evaluated KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, combined with LENVIMA® (lenvatinib)-an oral multi-receptor tyrosine kinase inhibitor developed by Eisai-alongside chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-negative gastroesophageal adenocarcinoma.
• In June 2024, Arcus Biosciences has completed patient enrollment for the Phase III STAR-221 clinical trial, which evaluates the combination of domvanalimab and zimberelimab with chemotherapy in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (upper GI cancers). Domvanalimab is an Fc-silent anti-TIGIT antibody, while zimberelimab is an anti-PD-1 monoclonal antibody. Both therapies are currently under investigation.
• In 2023, the total number of incident cases of gastroesophageal adenocarcinoma exceeded 220,000 across the 7MM.
• In 2023, Japan recorded the highest number of incident cases of gastroesophageal adenocarcinoma among the 7MM.
• In the US, Stage IV had the highest number of incident cases of gastroesophageal adenocarcinoma, whereas Japan reported the most cases in Stage I.
• Key Gastroesophageal Adenocarcinoma Companies: Merck, Taiho Pharmaceuticals, Sichuan Kelun-Biotech, ALX Oncology, Canadian Cancer Trials Group, AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., CSPC ZhongQi Pharmaceutical, Jazz Pharmaceuticals, Daiichi Sankyo, RemeGen Co., Ltd., LianBio LLC, Hoffmann-La Roche, Amgen, Phanes Therapeutics, and others.
• Key Gastroesophageal Adenocarcinoma Therapies: KEYTRUDA (pembrolizumab), LONSURF (trifluridine/ tipiracil), Sacituzumab Tirumotecan (MK-2870), Evorpacept (ALX148), Paclitaxel, Trifluridine-Tipiracil, ASKB589, AK104, OBP-301, tucatinib, Docetaxel for injection (Albumin-bound), Zanidatamab, Trastuzumab deruxtecan, Capecitabine, Infigratinib, Atezolizumab, Bemarituzumab, PT886, and others
• The Gastroesophageal Adenocarcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroesophageal Adenocarcinoma pipeline products will significantly revolutionize the Gastroesophageal Adenocarcinoma market dynamics.

Gastroesophageal Adenocarcinoma Overview
Gastroesophageal adenocarcinoma is a type of cancer that arises from the glandular cells lining the esophagus and the stomach. It is characterized by the abnormal growth of these cells, which can lead to the formation of tumors. This cancer often develops at the junction of the esophagus and stomach (gastroesophageal junction) and is associated with risk factors such as obesity, gastroesophageal reflux disease (GERD), smoking, and a diet low in fruits and vegetables. Symptoms may include difficulty swallowing, weight loss, chest pain, and persistent heartburn. Diagnosis typically involves imaging tests, endoscopy, and biopsy. Treatment options may include surgery, chemotherapy, radiation therapy, or targeted therapies, depending on the cancer's stage and the patient's overall health.

Get a Free sample for the Gastroesophageal Adenocarcinoma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/gastroesophageal-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastroesophageal Adenocarcinoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastroesophageal Adenocarcinoma Epidemiology Segmentation:
The Gastroesophageal Adenocarcinoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Gastroesophageal Adenocarcinoma
• Prevalent Cases of Gastroesophageal Adenocarcinoma by severity
• Gender-specific Prevalence of Gastroesophageal Adenocarcinoma
• Diagnosed Cases of Episodic and Chronic Gastroesophageal Adenocarcinoma

Download the report to understand which factors are driving Gastroesophageal Adenocarcinoma epidemiology trends @ Gastroesophageal Adenocarcinoma Epidemiology Forecast
https://www.delveinsight.com/sample-request/gastroesophageal-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastroesophageal Adenocarcinoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroesophageal Adenocarcinoma market or expected to get launched during the study period. The analysis covers Gastroesophageal Adenocarcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Gastroesophageal Adenocarcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroesophageal Adenocarcinoma Therapies and Key Companies
• KEYTRUDA (pembrolizumab): Merck
• LONSURF (trifluridine/ tipiracil): Taiho Pharmaceuticals
• Sacituzumab Tirumotecan (MK-2870): Merck/Sichuan Kelun-Biotech
• Evorpacept (ALX148): ALX Oncology
• Paclitaxel: Canadian Cancer Trials Group
• Trifluridine-Tipiracil: Merck Sharp & Dohme LLC
• ASKB589: AskGene Pharma, Inc.
• AK104: Akeso
• OBP-301: Weill Medical College
• tucatinib: Seagen Inc.
• Docetaxel for injection (Albumin-bound): CSPC ZhongQi Pharmaceutical
• Zanidatamab: Jazz Pharmaceuticals
• Trastuzumab deruxtecan: Daiichi Sankyo
• Capecitabine: RemeGen Co., Ltd.
• Infigratinib: LianBio LLC
• Atezolizumab: Hoffmann-La Roche
• Bemarituzumab: Amgen
• PT886: Phanes Therapeutics

Discover more about therapies set to grab major Gastroesophageal Adenocarcinoma market share @ Gastroesophageal Adenocarcinoma Treatment Landscape
https://www.delveinsight.com/sample-request/gastroesophageal-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastroesophageal Adenocarcinoma Market Drivers
• Increasing Incidence Rates
• Advancements in Treatment
• Improved Diagnostic Techniques
• Aging Population
• Rising Awareness
• Clinical Trials and Research

Gastroesophageal Adenocarcinoma Market Barriers
• High Treatment Costs
• Limited Early Detection
• Side Effects of Treatment
• Drug Resistance
• Regulatory Hurdles
• Geographical Disparities

Scope of the Gastroesophageal Adenocarcinoma Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gastroesophageal Adenocarcinoma Companies: Merck, Taiho Pharmaceuticals, Sichuan Kelun-Biotech, ALX Oncology, Canadian Cancer Trials Group, AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., CSPC ZhongQi Pharmaceutical, Jazz Pharmaceuticals, Daiichi Sankyo, RemeGen Co., Ltd., LianBio LLC, Hoffmann-La Roche, Amgen, Phanes Therapeutics, and others
• Key Gastroesophageal Adenocarcinoma Therapies: KEYTRUDA (pembrolizumab), LONSURF (trifluridine/ tipiracil), Sacituzumab Tirumotecan (MK-2870), Evorpacept (ALX148), Paclitaxel, Trifluridine-Tipiracil, ASKB589, AK104, OBP-301, tucatinib, Docetaxel for injection (Albumin-bound), Zanidatamab, Trastuzumab deruxtecan, Capecitabine, Infigratinib, Atezolizumab, Bemarituzumab, PT886, and others
• Gastroesophageal Adenocarcinoma Therapeutic Assessment: Gastroesophageal Adenocarcinoma current marketed and Gastroesophageal Adenocarcinoma emerging therapies
• Gastroesophageal Adenocarcinoma Market Dynamics: Gastroesophageal Adenocarcinoma market drivers and Gastroesophageal Adenocarcinoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Gastroesophageal Adenocarcinoma Unmet Needs, KOL's views, Analyst's views, Gastroesophageal Adenocarcinoma Market Access and Reimbursement

To know more about Gastroesophageal Adenocarcinoma companies working in the treatment market, visit @ Gastroesophageal Adenocarcinoma Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/gastroesophageal-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Gastroesophageal Adenocarcinoma Market Report Introduction
2. Executive Summary for Gastroesophageal Adenocarcinoma
3. SWOT analysis of Gastroesophageal Adenocarcinoma
4. Gastroesophageal Adenocarcinoma Patient Share (%) Overview at a Glance
5. Gastroesophageal Adenocarcinoma Market Overview at a Glance
6. Gastroesophageal Adenocarcinoma Disease Background and Overview
7. Gastroesophageal Adenocarcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Gastroesophageal Adenocarcinoma
9. Gastroesophageal Adenocarcinoma Current Treatment and Medical Practices
10. Gastroesophageal Adenocarcinoma Unmet Needs
11. Gastroesophageal Adenocarcinoma Emerging Therapies
12. Gastroesophageal Adenocarcinoma Market Outlook
13. Country-Wise Gastroesophageal Adenocarcinoma Market Analysis (2020-2034)
14. Gastroesophageal Adenocarcinoma Market Access and Reimbursement of Therapies
15. Gastroesophageal Adenocarcinoma Market Drivers
16. Gastroesophageal Adenocarcinoma Market Barriers
17. Gastroesophageal Adenocarcinoma Appendix
18. Gastroesophageal Adenocarcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Gastroesophageal Adenocarcinoma Epidemiology https://www.delveinsight.com/report-store/gastroesophgeal-adenocarcinoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Gastroesophageal Adenocarcinoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Gastroesophageal Adenocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.